HIV pre-exposure prophylaxis (PrEP)
PrEP · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
PrEP is antiretroviral medication taken by HIV-negative people at substantial risk to prevent acquisition. Oral tenofovir/emtricitabine is highly effective; long-acting injectable cabotegravir is an alternative. HIV must be excluded before and monitored during use.
Red flags
- Symptoms of acute HIV at or near initiation
- New seroconversion on PrEP (switch to full ART)
- Rising creatinine or declining GFR
- Hepatitis B flare after abrupt tenofovir cessation
Assessment
Differential diagnosis
- Undiagnosed acute HIV (contraindicates PrEP alone)
- Chronic hepatitis B (affects tenofovir choice/stopping)
- Renal impairment limiting tenofovir disoproxil
- Established HIV requiring full ART
- Other STI needing treatment
Investigations
- Fourth-generation HIV antigen/antibody test (and viral load if acute suspected)
- Renal function and estimated GFR
- Hepatitis B surface antigen and immunity status
- STI screen (gonorrhoea, chlamydia, syphilis)
- Pregnancy test where relevant
- Creatinine at baseline and during follow-up
Management
- Confirm HIV-negative with recent test; exclude acute seroconversion symptoms
- Assess ongoing HIV risk and eligibility
- Check renal function and hepatitis B status
- Counsel on daily (or event-based for eligible men) dosing and adherence
- Prescribe tenofovir disoproxil/emtricitabine, or offer injectable cabotegravir if preferred/eligible
- Advise condoms and screen/treat concurrent STIs
- Vaccinate against hepatitis B, hepatitis A, HPV and mpox where indicated
- Review at 1 month then every 3 months with repeat HIV test, STI screen and renal check
- Plan PrEP-to-ART transition immediately if HIV diagnosed
- Support safe stopping with tail cover; manage hepatitis B flare risk on discontinuation
Drugs & doses
Tenofovir disoproxil/emtricitabine 245/200 mg PO once daily
Event-based (2-1-1): two tablets 2-24 h before sex, one at 24 h, one at 48 h (eligible cisgender men)
Cabotegravir long-acting 600 mg IM at 0 and 1 month then every 2 months
Cabotegravir 30 mg PO once daily oral lead-in (optional before injectable)
Disposition
Sexual health / HIV prevention clinic; routine follow-up; urgent review if seroconversion.
Complications & pitfalls
- Breakthrough HIV with integrase resistance (notably on injectable)
- Renal toxicity with tenofovir disoproxil
- Bone mineral density reduction
- Hepatitis B reactivation on stopping
- Ongoing STI acquisition
Exam pearls
- Daily oral PrEP is near-fully protective with good adherence
- Event-based dosing is validated only for anal sex in cisgender men
- Injectable cabotegravir requires 3-monthly HIV RNA monitoring given risk of occult infection
- Tenofovir alafenamide/emtricitabine is an option where renal/bone concerns exist (not for receptive vaginal exposure data-wise)
- Always exclude acute HIV before starting
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.